Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2011 2
2012 5
2013 1
2014 3
2015 4
2016 3
2017 1
2018 3
2019 6
2020 4
2021 17
2022 22
2023 15
2024 6

Text availability

Article attribute

Article type

Publication date

Search Results

80 results

Results by year

Filters applied: . Clear all
Page 1
Nivolumab + Ipilimumab as Immunotherapeutic Boost in Metastatic Urothelial Carcinoma: A Nonrandomized Clinical Trial.
Grimm MO, Schostak M, Grün CB, Loidl W, Pichler M, Zimmermann U, Schmitz-Dräger B, Steiner T, Roghmann F, Niegisch G, Bolenz C, Schmitz M, Baretton G, Leucht K, Schumacher U, Foller S, Zengerling F, Meran J; TITAN-TCC Study Group. Grimm MO, et al. Among authors: zengerling f. JAMA Oncol. 2024 May 9. doi: 10.1001/jamaoncol.2024.0938. Online ahead of print. JAMA Oncol. 2024. PMID: 38722641
Improving detection of carcinoma in situ in bladder cancer: urinary cytology vs the Xpert® BC Monitor.
Haas M, Kriegmair MC, Breyer J, Sikic D, Wezel F, Roghmann F, Brehmer M, Wirtz RM, Jarczyk J, Erben P, Bahlinger V, Goldschmidt F, Fechner G, Chen J, Paxinos E, Bates M, Zengerling F, Bolenz C, Burger M, Hartmann A, Eckstein M. Haas M, et al. Among authors: zengerling f. BJU Int. 2024 May 8. doi: 10.1111/bju.16389. Online ahead of print. BJU Int. 2024. PMID: 38717014
NECTIN4 Amplification Is Frequent in Solid Tumors and Predicts Enfortumab Vedotin Response in Metastatic Urothelial Cancer.
Klümper N, Tran NK, Zschäbitz S, Hahn O, Büttner T, Roghmann F, Bolenz C, Zengerling F, Schwab C, Nagy D, Toma M, Kristiansen G, Heers H, Ivanyi P, Niegisch G, Grunewald CM, Darr C, Farid A, Schlack K, Abbas M, Aydogdu C, Casuscelli J, Mokry T, Mayr M, Niedersüß-Beke D, Rausch S, Dietrich D, Saal J, Ellinger J, Ritter M, Alajati A, Kuppe C, Meeks J, Vera Badillo FE, Nakauma-González JA, Boormans J, Junker K, Hartmann A, Grünwald V, Hölzel M, Eckstein M. Klümper N, et al. Among authors: zengerling f. J Clin Oncol. 2024 Apr 24:JCO2301983. doi: 10.1200/JCO.23.01983. Online ahead of print. J Clin Oncol. 2024. PMID: 38657187
Enfortumab Vedotin and Pembrolizumab in Untreated Advanced Urothelial Cancer.
Powles T, Valderrama BP, Gupta S, Bedke J, Kikuchi E, Hoffman-Censits J, Iyer G, Vulsteke C, Park SH, Shin SJ, Castellano D, Fornarini G, Li JR, Gümüş M, Mar N, Loriot Y, Fléchon A, Duran I, Drakaki A, Narayanan S, Yu X, Gorla S, Homet Moreno B, van der Heijden MS; EV-302 Trial Investigators. Powles T, et al. N Engl J Med. 2024 Mar 7;390(10):875-888. doi: 10.1056/NEJMoa2312117. N Engl J Med. 2024. PMID: 38446675 Clinical Trial.
Detection of Recurrence through microRNA-371a-3p Serum Levels in a Follow-up of Stage I Testicular Germ Cell Tumors in the DRKS-00019223 Study.
Belge G, Dumlupinar C, Nestler T, Klemke M, Törzsök P, Trenti E, Pichler R, Loidl W, Che Y, Hiester A, Matthies C, Pichler M, Paffenholz P, Kluth L, Wenzel M, Sommer J, Heinzelbecker J, Schriefer P, Winter A, Zengerling F, Kramer MW, Lengert M, Frey J, Heidenreich A, Wülfing C, Radtke A, Dieckmann KP. Belge G, et al. Among authors: zengerling f. Clin Cancer Res. 2024 Jan 17;30(2):404-412. doi: 10.1158/1078-0432.CCR-23-0730. Clin Cancer Res. 2024. PMID: 37967143 Free PMC article.
Early CRP kinetics to predict long-term efficacy of first-line immune-checkpoint inhibition combination therapies in metastatic renal cell carcinoma: an updated multicentre real-world experience applying different CRP kinetics definitions.
Hoeh B, Garcia CC, Banek S, Klümper N, Cox A, Ellinger J, Schmucker P, Hahn O, Mattigk A, Zengerling F, Becker P, Erdmann K, Buerk BT, Flegar L, Huber J, Kalogirou C, Zeuschner P. Hoeh B, et al. Among authors: zengerling f. Clin Transl Immunology. 2023 Oct 25;12(10):e1471. doi: 10.1002/cti2.1471. eCollection 2023. Clin Transl Immunology. 2023. PMID: 37899949 Free PMC article.
Loss of ORP3 induces aneuploidy and promotes bladder cancer cell invasion through deregulated microtubule and actin dynamics.
Wang X, Liu J, Azoitei A, Eiseler T, Meessen S, Jiang W, Zheng X, Makori AW, Eckstein M, Hartmann A, Stilgenbauer S, Elati M, Hohwieler M, Kleger A, John A, Zengerling F, Wezel F, Bolenz C, Günes C. Wang X, et al. Among authors: zengerling f. Cell Mol Life Sci. 2023 Sep 22;80(10):299. doi: 10.1007/s00018-023-04959-6. Cell Mol Life Sci. 2023. PMID: 37740130 Free PMC article.
Xpert bladder cancer monitor to predict the need for a second TURB (MoniTURB trial).
Breyer J, Eckstein M, Sikic D, Wezel F, Roghmann F, Brehmer M, Wirtz RM, Jarczyk J, Erben P, Bahlinger V, Goldschmidt F, Fechner G, Chen J, Paxinos E, Bates M, Haas M, Zengerling F, Bolenz C, Burger M, Hartmann A, Kriegmair MC; BRIDGE Consortium e.V.. Breyer J, et al. Among authors: zengerling f. Sci Rep. 2023 Sep 18;13(1):15437. doi: 10.1038/s41598-023-42088-z. Sci Rep. 2023. PMID: 37723173 Free PMC article.
80 results